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Dementia with Lewy bodies (DLB) is characterized by fluctuation in
cognition and attention. Thalamocortical connectivity and integrity of
thalami are central to attentional function. We hypothesize that DLB
patients with marked and frequent fluctuating cognition (flCog) have a
loss of thalamocortical connectivity, an intrinsic disruption to thalamic
structure and imbalances in thalamic neurotransmitter levels. To test
this, magnetic resonance imaging (MRI), diffusion tensor imaging (DTI)
and proton MR spectroscopy on thalami were performed on 16 DLB,
16 Alzheimer’s disease (AD) and 13 healthy subjects. MRI and DTI
were combined to subdivide thalami according to their cortical con-
nectivity and to investigate microstructural changes in connectivity-
defined thalamic regions. Compared with controls, lower N-acetyl-
aspartate/total creatine (NAA/tCr) and higher total choline/total creat-
ine (tCho/tCr) values were observed within thalami of DLB patients.
tCho/tCr increase was found within right thalamus of DLB patients as
compared with AD. This increase correlated with severity and fre-
quency of flCog. As compared with controls, DLB patients showed bi-
lateral damage within thalamic regions projecting to prefrontal and
parieto-occipital cortices, whereas AD patients showed bilateral alter-
ation within thalamic region projecting to temporal cortex. We posit
that microstructural thalamic damage and cholinergic imbalance may
be central to the etiology of flCog in DLB.
Keywords: attention, choline, dementia with Lewy bodies, fluctuating
cognition, thalamus
Introduction
The thalamus plays a central role in altering and maintaining
arousal (Steriade 2006; Ward 2011). Anatomically, its nuclei are
topographically organized to modulate and synchronize distrib-
uted cortical networks supporting large-scale cerebral dynamics
related to goal-directed behaviors and awareness (Schiff 2008).
On this basis, it was suggested that phenomenal consciousness
is generated by synchronized neural activity in thalamic neurons
and that thalamic activity is driven by information arising from
the cortical computation (Ward 2011).
Abnormal functional connectivity and microstructural damage
within thalami have been previously reported in dementia with
Lewy bodies (DLB) (Watson et al. 2012; Kenny et al. 2013). DLB
patients were clinically characterized by spontaneous alteration
in cognition, attention, and arousal (Lee et al. 2012). These symp-
toms were reported as fluctuating cognition (flCog), which re-
presents, together with visual hallucinations and extrapyramidal
signs, the core clinical features of DLB (McKeith et al. 2005).
Several neuroimaging studies have focused on the neural
bases of flCog in DLB patients, suggesting a relation between
the severity of flCog and covariant perfusional network changes
(Taylor et al. 2013) or functional magnetic resonance imaging
(fMRI) blood oxygen-dependent level (BOLD) (Franciotti et al.
2013; Peraza et al. 2014) alterations. In addition, increased thal-
amic perfusion on single photon emission computed tomography
(SPECT) (O’Brien et al. 2005) and changes in dopaminergic and
cholinergic systems within thalami have been linked to flCog in
DLB (Pimlott et al. 2006; Piggott et al. 2007). Of note, the cholin-
ergic system is widely distributed in the brain and it is more af-
fected in DLB than in Alzheimer’s disease (AD) patients (Kotagal
et al. 2012). This concept is amply supported by pharmacological
evidences which suggest that (1) anticholinergic drugs can induce
a symptom profile of altered arousal comparable to flCog in DLB
(Perry et al. 1999) and (2) cholinesterase inhibitors can significant-
ly improve flCog and attentional function in DLB (McKeith et al.
2000; Onofrj et al. 2003; Wesnes et al. 2005).
Based on these considerations and on the central role of thalam-
ic neurons in regulating arousal and attention, we hypothesized
that cholinergic imbalancewithin thalami and damage of the struc-
tural connectivity between thalami and cortical regionsmodulating
alertness and attention are associated with flCog in DLB.
To test this, we carried out a study using multimodal techni-
ques including structural magnetic resonance imaging (MRI),
diffusion tensor imaging (DTI) and proton MR Spectroscopy
(1H-MRS) in a cohort of DLB and AD patients as well as healthy
controls. 1H-MRS technique assesses, in vivo, different metabo-
lites such as N-acetyl-aspartate (NAA) and total choline (tCho)
which are specifically related to decrease of neuronal integrity
and to cholinergic deficits respectively. The combination of
structural MRI and DTI allows parcellation of the thalami
according to their cortical structural connectivity and to investi-
gate microstructural integrity in each connectivity-defined
region. The comparison between DLB and AD was performed
to assess whether any possible structural and metabolic
changes in the thalami were specific of a dementia character-
ized by the presence of flCog (DLB) or more as a result of a
process of dementia per se. Furthermore, the variation of se-
verity and frequency of flCog among DLB patients provides a
means by which to assess whether the MR thalamic changes
are associated with more overt flCog.
Material and Methods
Study Sample
This study was approved by Local Institutional Ethics Committee. All
participants (or their caregivers) gave written informed consent.
© The Author 2014. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.
permissions@oup.com
Cerebral Cortex
doi:10.1093/cercor/bhu220
 Cerebral Cortex Advance Access published September 26, 2014
 at U
niversity of N
ew
castle on July 2, 2015
http://cercor.oxfordjournals.org/
D
ow
nloaded from
 
Sixteen AD and 16 DLB patients were recruited from our Memory
Clinic and Movement Disorder Clinic. Thirteen age-matched volunteers
come from our nondemented case register cohorts. The diagnosis of
probable AD was made using National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer’s Disease and Related
Disorders Association criteria (McKhann et al. 1984). The probable
DLB diagnosis was based on consensus guidelines (McKeith et al.
2005) with a specific restriction: we included only patients with the
presence of flCog, plus at least one additional core feature (visual hallu-
cination or parkinsonism) or the presence of flCog plus one or more
suggestive features (McKeith et al. 2005).
As part of their clinical work up within 6 months before the inclusion
in the study, all patients underwent computerized tomography or MRI and
dopaminergic presynaptic ligand ioflupane SPECT (DAT scan). In addition
all patients were assessed with electroencephalography (EEG) recordings
as abnormalities characterized by parieto-occipital dominant frequency
alterations have previously been shown to reliably differentiate probable
DLB from AD (Bonanni et al. 2008). DAT scans and EEG Compressed
Spectral Array patterns (as defined in Bonanni et al. 2008), performed
prior to entry into the study, were used to support the diagnosis of DLB.
Clinical Evaluation
Mini mental state examination (MMSE), clinical dementia rating (CDR)
and Dementia rating scale-2 (DRS-2) (Jurica et al. 2001) were per-
formed for global cognitive assessment. Frontal assessment battery
(FAB) was performed to evaluate the severity of frontal dysfunction
(Dubois et al. 2000). The frequency and duration of flCog were as-
sessed by CAF questionnaire (Walker et al. 2000); this is a well estab-
lished tool and while it has been superseded by scales which may have
better diagnostic utility in distinguishing flCog in DLB compared with
AD (e.g., dementia cognitive fluctuation scale, Lee et al. 2013), the CAF
remains validated as a measure of the severity and frequency of flCog
and has been used in numerous studies as a metric to examine the
pathophysiological basis of flCog (Ballard, O’Brien et al. 2001; Ballard,
Walker et al. 2001b; Bonanni et al. 2008; Taylor et al. 2013; Peraza et al.
2014). A CAF score between 2 and 16 was considered sufficient to
define a patient as affected by flCog (Bonanni et al. 2008). Based on
this criterion only a 2% of our DLB selected population was excluded
from the study. AD patients were selected on the basis of having no
clinical history of flCog (CAF score of zero). Extrapyramidal signs were
assessed using the motor part of the Unified Parkinson’s Disease
Rating Scale (UPDRS) III (Fahn and Elton 1987). The Neuropsychiatric
Inventory (NPI) scale was used to evaluate neuropsychiatric features
(Cummings et al. 1994). The NPI hallucinations item-2 scale was per-
formed to investigate the occurrence and severity of visual hallucina-
tions. Minimal International Classification of Sleep Disorders criteria
were used to assess REM sleep behavior disorder (RBD) (World Health
Organization 1992). Since 1H-MRS spectra are sensitive to phar-
macological manipulations (Gomez et al. 2012; Stone et al. 2012;
Karczewska-Kupczewska et al. 2013), pharmacological treatments
were withdrawn on the day of MR session (Onofrj et al. 2003; Burn
et al. 2006; Franciotti et al. 2013).
MRProtocol
All MR data were acquired with a Philips Achieva 3 T scanner (Philips
Medical System, Best, the Netherlands) equipped with 8-channel re-
ceiver coil. Three-dimensional T1-weighted images were acquired by
using Turbo Field-Echo sequence (TFE, TR/TE = 11/5 ms, slice thick-
ness of 0.8 mm). Two 1H-MRS voxels of 1.5 × 1.0 × 1.5 mm3 were accur-
ately placed on right and left thalami, respectively (Fig. 1A).
Point-resolved spectroscopy sequences (TR/TE = 2000/39 ms, 16-step
phase-cycle and an average of 128 scan) with and without water sup-
pression were performed by using chemically shift selective (CHESS)
pulses. One thousand and twenty-four points were acquired with a
spectral width of 2000 Hz. T2-weighted fluid attenuation inversion re-
covery sequence [FLAIR, time repetition (TR)/time echo (TE) = 11 000/
125 ms, slice thickness of 4 mm, field of view (FOV) = 240 × 129 × 222
mm] was performed to exclude participants with concomitant vascular
pathology or with white matter abnormalities outside the normal range.
1H-MRS Analysis
1H-MRS data analysis was performed by using JMRUI version 4.0
(Naressi et al. 2001). Spectra with water suppression were filtered for
removal of residual water by using the Hankel Lanczos Singular Values
Decomposition algorithm. After autophasing, baseline and frequency
shifts correction, a priori knowledge database (NAA, 2.02 ppm; total
creatine = tCr, 3.03 ppm; tCho, 3.22 ppm) was created to put con-
straints on the advanced magnetic resonance fitting algorithm within
jMRUI package. Peak shifts were restricted to ±5 ppm of the theoretical
location. Spectra with artifact and metabolites fits with Cramer Rao
Lower Bounds >20% were excluded.
For applicability to the clinical practice and because several 1H-MRS
studies report stable tCr levels in dementias (Valenzuela and Sachdev
2001; Dedeoglu et al. 2004; Chao et al. 2005; Kantarci 2013), we ex-
pressed NAA and tCho relatively to tCr. By using spectra without water
suppression, we calculated the area of the water peak and we used
it as an internal reference standard for absolute tCr quantification
(Christiansen et al. 1993; Delli Pizzi et al. 2012, 2013).
Parcellation of Thalami
Functional MRI of the Brain (FMRIB) Software Library (FSL, version
5.0; http://www.fmrib.ox.ac.uk/fsl, Smith et al. 2004) was used to
perform structural connectivity-based parcellation of thalami and to in-
vestigate microstructural changes in each thalamic region. For each
subject, mean diffusivity (MD) maps were generated from a tensor-
model fit in FSL (FDT, FMRIB’s Diffusion Toolbox). Thalami parcella-
tion was performed according to methods described by Behrens et al.
(2003). Four cortical masks including prefrontal, sensorimotor, tem-
poral, and parieto-occipital regions were defined using the Harvard
Oxford Cortical Atlas (implemented in FSL) (Fig. 2A). The composition
of each target region was reported in Supplementary Table 1. FMRIB’s
Integrated Registration and Segmentation Tool (FIRST) was used to
automatically segment thalami (Patenaude et al. 2011) and its outputs
were binarized to obtain masks. All cortical and subcortical masks
were in MNI space (1 × 1 × 1 mm). After Bayesian estimation of diffu-
sion parameters obtained using sampling techniques, the DTI maps
were registered to MNI standard space using: (1) FLIRT to register each
subject’s b0 image to its native structural image, and (2) FMRIB’s non-
linear registration tools to register the structural and diffusion images
to MNI space (1 × 1 × 1 mm). All masks were then propagated onto
each individual’s DTI scalar maps using the inverse of the above trans-
formations. To exclude thalamic voxels that contained cerebrospinal
fluid (CSF), the b0 images were segmented using FMRIB’s Automated
Segmentation Tool (FAST) and CSF binarized to be used as exclusion
mask. To exclude voxels out of the thalamic range, manual editing was
applied where needed. Next, probabilistic tracking was carried out by
probabilistic tracking (PROBTRACKX) tool. “Find the biggest”
command line was used to define the thalamic connectivity-defined
subregions according to their highest probability of connection with
cortical regions (Fig. 2B). Two experienced operators visually in-
spected the “find the biggest” outputs, verifying the anatomic corres-
pondence of each thalamic connectivity-defined subregion among
subjects and their accordance with Oxford Thalamic Connectivity Atlas
(integrated in FSL, Johansen-Berg et al. 2005; Fig. 2C).
Finally, MD values were calculated in each connectivity-defined sub-
region.
Given that some cortical regions in DLB and/or AD could be charac-
terized by changes in regional cerebral blood flow (Colloby et al. 2013)
and the diffusion indices could be biased by different location and
volume of thalamic connectivity-defined regions determined by the
tracking algorithm, we adopted 3 different strategies. Firstly, we veri-
fied whether the spatial distribution and the connection probability
within each thalamic connectivity-defined region were altered by the
pathological underlying condition (Nair et al. 2013). Specifically, by
using “randomize” command line, we carried out comparisons within
and between groups on the maps of connection probability generated
by PROBTRACKX (Fig. 2D). Family-wise error (FEW) correction was
applied to obtain the significant voxels. Secondly, we verified whether
the volumes of each thalamic region defined by “find the biggest” were
significantly different among groups. Specifically, for each subject, the
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Figure 1. Proton magnetic resonance spectroscopy (1H-MRS). (A) Two voxels of 1.5 × 1.0 × 1.5 mm3 were, respectively, placed on right and left thalami by using T1-weighted
image as anatomical reference. (B) Representative spectra for DLB, AD, and controls. Estimated signals (violet) were reported on original signals (red). NAA, N-acetyl-aspartate
(2.02 ppm); tCr, total creatine (3.03 ppm); tCho, total choline (3.22 ppm). (C) Scatterplot expresses the linear regression between CAF scores and tCho/tCr values in the right
thalamus. AD, Alzheimer’s disease; DLB, dementia with Lewy bodies. Values marked with an asterisk are overlapped.
Figure 2. Structural connectivity. (A) Cortical rendering of target regions used for thalami parcellation (colors were in agreement with thalamic connectivity). (B) Connectivity-based
subdivision of thalami for controls (CON), dementia with Lewy bodies (DLB), and Alzheimer’s disease (AD). Thalamic voxels are classified and colored according to the highest
probability of connection to specific cortical regions. Red, connectivity-defined subregion (CDR) that projects from thalamus to prefrontal cortex; blue, CDR that projects from
thalamus to sensorimotor cortex; yellow, CDR that projects from thalamus to parieto-occipital cortex; green, CDR that projects from thalamus to temporal cortex. (C) Thalami
regions defined by Oxford Thalamic Connectivity Atlas. (D) Within-group probabilistic tractography maps for each cortical target region. The significant results are shown by voxels
rating from red to yellow (P<0.05, FWE-corrected). No significant differences were found among groups. PFC, prefrontal; SM, sensorimotor; PO, parieto-occipital; TMP, temporal.
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volumes of thalamic regions were calculated by “fslstats” command
line and, next, they were normalized for ipsilateral thalamic volume.
Third, we verified whether the MD values in each thalamic region were
related to differences found by tracking probability. Specifically, we
defined the thalamic regions from Oxford thalamic connectivity atlas
and we extracted MD values from them. Finally, we performed multi-
variate analysis of variance (MANOVA) on MD values to test whether
the 2 methods (probabilistic parcellation and atlas) provided different
results for thalamic regions.
Statistical Analysis
Analysis of variance (ANOVA) among groups was carried out on demo-
graphic and clinical data. χ2 test was carried out for gender.
We performed multivariate analysis of covariance (MANCOVA) to
exclude the possible effect of cognitive impairment on different imaging
findings obtained from demented patients and controls. Next, MANOVA
was carried out to test the differences among groups (AD, DLB, and con-
trols). Tukey’s HSD post hoc test was performed for assessing pair-wise
differences between groups. For all comparisons, significance level was
set at P < 0.05.
Linear regression was performed to assess the relationship between
MR outcomes in DLB patients (MD within right and left connectivity-
defined subregions and metabolites/tCr within left and right thalami)
and CAF scores (our primary clinical measure). Age, MMSE, NPI
hallucination-item, UPDRS scores were included as nuisance factors.
All results were corrected for multiple comparisons using Bonferroni’s
correction (P = 0.05/12 = 0.004).
Results
Demographic and Clinical Features
Table 1 summarizes demographic features and neuropsycho-
logical test scores. Groups did not differ for age, gender, and
educational level. CAF scores ranged between 2 and 12 in DLB
patients. All DLB patients showed an abnormal quantitative
EEG pattern profile consistent with a DLB diagnosis (Bonanni
et al. 2008) and represented by slow dominant frequency (in
the theta and prealpha band) in posterior leads and a dominant
frequency variability >1.5 Hz. None of the AD patients or con-
trols showed these DLB-specific EEG characteristics (Bonanni
et al. 2008). No differences on global test of cognition and on
severity of frontal dysfunction were reported between AD and
DLB patients. Fourteen DLB patients had RBD. Dopamine-
transporter hypocaptation in the caudate nuclei at SPECT-DAT
scan was observed in all DLB patients, and it was bilateral in 12
patients. SPECT-DAT scan abnormalities were not observed in
AD patients or control subjects.
The patients were on a range of medications including L-Dopa
(all DLB patients), rivastigmine or donepezil (all AD and DLB pa-
tients with no differences in daily dosages between the 2 groups
of patients), quetiapine (8 DLB and 6 AD), clozapine (4 DLB),
and risperidone (4 AD) and clonazepam (the 14 DLB patients
with RBD).
1H-MRS Findings
Table 2 summarizes 1H-MRS results. Figure 1B shows represen-
tative spectra for each group. Supplementary Table 2 shows
the effects among groups from MANCOVA and MANOVA ana-
lyses. Lower NAA/tCr and higher tCho/tCr values were bilaterally
observed in the thalami of DLB patients respect to controls. No
changes were found in the thalami of AD patients compared
with controls. The comparison between DLB and AD demon-
strated tCho/tCr increase in the right thalamus of DLB patients.
No tCr changes were found among groups. Assuming as nuis-
ance factors age, MMSE, NPI hallucinations, UPDRS scores, on
linear regression a significant relationship between tCho/tCr and
CAF values within right thalamus (R = 0.86, t = 5.391, P < 0.001)
(Fig. 1C) was observed.
Thalamocortical Structural Connectivity
Figure 2B shows the thalamic connectivity-defined subregions
projecting to:
1. prefrontal cortex including the ventro-anterior and dorso-
medial parts of the thalami;
2. sensorimotor cortex including the ventrolateral part of the
thalami;
3. parieto-occipital cortex including the ventro-posterior part
of the thalami and the superior portion of pulvinar;
4. temporal cortex including the dorso-anterior part of the
thalami and the inferior portion of pulvinar.
Figure 2D shows the maps of connection probability of each
thalamic subregion to specific cortical regions, for each group.
When comparisons between groups were performed, no sig-
nificant differences were observed on connection probability.
As verified by visual inspection of “find the biggest” outputs, the
location of each connectivity-defined thalamic region showed
good correspondence among groups and it was in agreement
with Oxford Thalamic Connectivity Atlas (Fig. 2C). Furthermore,
the volumes of each thalamic region defined by “find the
biggest” were not different among groups (see Supplementary
Table 3). Hence, the anatomy for each thalamic connectivity-
defined region did not significantly change in pathological con-
ditions with respect to controls.
Mean Diffusivity Changes Within Thalamic Regions
Table 3 shows grand mean MD values for each connectivity-
defined subregion obtained from tractography-based subdivision
Table 1
Demographic and clinical features
Characteristics Controls AD DLB
Number of subjects/patients 13 16 16
Agea,b 75.6 ± 4.7 75.5 ± 5.4 75.6 ± 4.2
Male gender (%)c 46% 50% 50%
Disease duration (years)d – 3.1 ± 0.7 3.0 ± 0.6
Education level (years)a,e 7 ± 4 7 ± 3 7± 4
Clinical dementia ratinga,f – 2.3 ± 0.6 2.3 ± 0.7
Mini mental state examinationa,g 28.3 ± 1.3 17.7 ± 4.5 17.9 ± 4.5
Dementia rating scalea,h 136.6 ± 0.7 91.4 ± 18.1 91.7 ± 15.8
Frontal assessment batterya,i 17.6 ± 0.5 8.4 ± 2.7 8.6 ± 2.7
Clinician assessment of fluctuations 0.0 ± 0.0 0.0 ± 0.0 4.9 ± 2.9
Unified Parkinson’s disease rating scale III 0.0 ± 0.0 0.0 ± 0.0 25.8 ± 10.0
Neuropsychiatric inventory-item 2 hallucinations 0.0 ± 0.0 0.0 ± 0.0 4.0 ± 1.8
Note: Values are expressed as mean ± standard deviation.
aThe P-values were calculated using the one-way ANOVA; Tukey ’’s HSD post hoc test was also
performed when F-test was significant.
bMain interaction among groups: F2,44 = 0.003, P= 0.997.
cThe P-values were calculated using χ² test: χ²1 = 0.022, P= 0.881.
dThe P-values were calculated using the independent-samples t-test: t30 =−0.522, P= 0.605.
eMain interaction among groups: F2,44 = 0.846, P= 0.436.
fThe P-values were calculated using the independent-samples t-test: t30 =−0.275; P= 0.786.
gMain interaction among groups: F2,44 = 34.223, P< 0.001; post hoc: controls versus AD,
P< 0.001; controls versus DLB, P< 0.001 and AD versus DLB, P= 0.982.
hMain interaction among groups: F2,44 = 45.367, P< 0.001; post hoc: controls versus AD,
P< 0.001; controls versus DLB, P< 0.001 and AD versus DLB, P= 0.998.
iMain interaction among groups: F2,44 = 74.363, P< 0.001; post hoc: controls versus AD,
P< 0.001; controls versus DLB, P< 0.001 and AD versus DLB, P= 0.987.
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of thalami. Supplementary Table 4 shows the effects among
groups from MANCOVA and MANOVA analyses. Supplementary
Table 5 shows grand mean MD values for each connectivity-
defined subregion obtained from Oxford thalamic connectivity
atlas. No differences were found between MD values obtained
with probabilistic parcellation and MD values obtained with
Oxford Thalamic Connectivity Atlas (see Supplementary Table 6).
In comparison to controls, DLB patients showed bilateral in-
creases in MD in the connectivity-defined subregions projecting
to the prefrontal and parieto-occipital cortices. As compared with
controls, AD patients showed increase of MD in left connectivity-
defined subregion projecting to the temporal cortex. No signifi-
cant differences were found in the comparison between DLB and
AD. Within the DLB group MD increases were not correlated
with our primary measure of flCog (CAF score) or other clinical
variables (e.g. FAB).
Discussion
In the current study, we demonstrated that DLB patients with flCog
were affected by neurochemical imbalance in the thalami and by
microstructural changes in the connectivity-defined regions pro-
jecting from thalamus to the frontal and parieto-occipital cortices.
Specifically, we found reduced NAA/tCr and increased
tCho/tCr in the thalami of DLB with flCog.
TCr is a neuronal marker of energetic metabolism. Because
its levels are typically stable in dementias (Kantarci 2013), tCr
has been used as internal reference in 1H-MRS studies on DLB
(Molina et al. 2002; Kantarci et al. 2004; Graff-Radford et al.
2014). Consistent with this, our results showed that tCr was ef-
fectively unchanged in our groups, and thus suggest that the
thalamic neurochemical alterations observed in our DLB pa-
tients are mainly attributable to NAA and tCho.
NAA is primarily located in neuron bodies, axons, and den-
drites and it is a sensitive marker for neuronal density or viabil-
ity (Kantarci 2013). Therefore, NAA reduction suggested that
DLB pathology could be associated to neurodegenerative pro-
cesses in the thalami. Notably, this finding is consistent with a
recent DTI study describing thalamic white matter disruption
in DLB patients (Watson et al. 2012).
TCho provides a marker of the contribution of cytosolic gly-
cerolphosphocholine and phosphocholine which are the pro-
ducts of membrane phosphatidyl choline breakdown and the
precursors of choline and acetylcholine synthesis, respectively
(Klein 2000). It was hypothesized that higher tCho levels in
DLB could be linked to the increase of membrane turnover
due to dying of the neuropil and to down-regulation of choline
acetyltransferase activity that it is reduced more severely in
DLB with respect to AD (Wurtman et al. 1985; MacKay et al.
1996; Tiraboschi et al. 2002; Kantarci 2013). In this context,
recent 1H-MRS studies have suggested that the increase in tCho
could be a characteristic feature of DLB and independent from
AD pathology (Kantarci 2013; Graff-Radford et al. 2014). Fur-
thermore, consistently with our findings on thalami, Kotagal
et al. (2012) observed thalamic cholinergic denervation in DLB
but not in AD, suggesting a relationship between neurodegen-
erative involvement of thalamic cholinergic afferent projec-
tions and cognitive alteration in DLB.
TCho/tCr values in the thalamus were closely correlated with
the presence and severity of flCog as assessed by CAF question-
naire. The cholinergic system is particularly implicated in atten-
tion and awareness (Perry et al. 1999; Klinkenberg et al. 2011).
Studies on DLB patients reported attentional performance im-
provement following the cholinesterase inhibitors treatment
(Wesnes et al. 2005). Furthermore, imaging studies observed
Table 3
Mean diffusivity values in each “connectivity-defined region” obtained from tractography-based parcellation of thalami
Connectivity-defined region Mean diffusivity (MD) Statistical comparisona
Target Thalamus Controls AD DLB AD versus controls DLB versus controls AD versus DLB
Prefrontal cortex Right 752 ± 15 785 ± 67 809 ± 52 P= 0.211 P= 0.014 P= 0.395
Left 752 ± 16 784 ± 72 815 ± 52 P= 0.257 P= 0.008 P= 0.243
Sensorimotor cortex Right 750 ± 19 757 ± 71 797 ± 60 P= 0.933 P= 0.079 P= 0.131
Left 750 ± 37 760 ± 80 801 ± 47 P= 0.876 P= 0.061 P= 0.136
Parieto-occipital cortex Right 759 ± 24 793 ± 88 843 ± 61 P= 0.365 P= 0.004 P= 0.085
Left 759 ± 28 798 ± 93 837 ± 59 P= 0.289 P= 0.010 P= 0.234
Temporal cortex Right 779 ± 20 828 ± 70 818 ± 52 P= 0.046 P= 0.134 P= 0.856
Left 782 ± 24 830 ± 59 818 ± 47 P= 0.024 P= 0.111 P= 0.757
Note: MD values (×10−4mm2/s) are expressed as mean ± standard deviation. Bold characters indicate statistically significant results. Significant mean differences were found among groups by MANOVA
(F16,70 = 3.124, P= 0.001).
aP-values from Tukey’s HSD post hoc.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies.
Table 2
Neurochemical changes in the thalami assessed by 1H-MRS
Metabolites Thalamus Controls AD DLB AD versus controlsa DLB versus controlsa AD versus DLBa
NAA/tCr Right 1.84 ± 0.12 1.73 ± 0.15 1.65 ± 0.2 P= 0.160 P= 0.008 P= 0.363
Left 1.82 ± 0.15 1.78 ± 0.19 1.68 ± 0.14 P= 0.738 P= 0.045 P= 0.173
tCho/tCr Right 0.72 ± 0.04 0.72 ± 0.07 0.8 ± 0.09 P= 0.996 P= 0.014 P= 0.011
Left 0.72 ± 0.05 0.76 ± 0.08 0.8 ± 0.11 P= 0.315 P= 0.034 P= 0.465
tCr/waterb Right 5.2 ± 0.2 5.1 ± 0.4 4.9 ± 0.9 P= 0.958 P= 0.414 P= 0.546
Left 5.2 ± 0.6 5.0 ± 0.7 5.0 ± 0.7 P= 0.733 P= 0.774 P= 0.997
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; NAA, N-acetyl-aspartate; tCr, total creatine; tCho, total choline.
aTukey’s HSD post hoc test was performed for assessing pair-wise differences between groups.
bValue × 10−4. Bold characters indicate statistically significant results. Significant mean differences were found among groups by MANOVA (F12,74 = 3.216, P= 0.001).
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cholinergic alterations related to flCog in the thalami of DLB pa-
tients (Perry et al. 1998; O’Brien et al. 2005; Pimlott et al. 2006).
Thus, this strongly favors the role of cholinergic imbalance
within thalami in the etiology of flCog in DLB.
In agreement with previous functional and structural studies
by our groups (Franciotti et al. 2006, 2013; Delli Pizzi et al.
2014), we also observed predominant right lateralization of
neurochemical alterations in DLB. These findings could be
linked to the dominant role of the right hemisphere in atten-
tion (Thiebaut de Schotten et al. 2011). Further studies inte-
grating structural and functional MRI techniques could clarify
whether predominant right hemispheric dysfunction is truly a
specific feature of DLB.
We observed that structural thalamocortical connectivity
was affected in DLB patients with flCog. In this context, MD
was specifically assessed because it is an index for both grey
and white matters damage and its high values are associated to
reduction in membrane density and cell loss of both neurons
and glia (Canu et al. 2010).
Thalamic neurons regulate the cortico-cortical control acting
as neuronal hub to synchronize oscillations between cortical areas
(Sherman 2007). Themodulation of thalamic activity can shift cor-
tical activity by desynchronizing activated states (depolarized
tonic firing mode) associated with arousal and/or by synchroniz-
ing deactivated states (burst firing mode) indicative of drowsiness
(Llinás and Steriade 2006; Hirata and Castro-Alamancos 2010). In
this context, impaired thalamic activity has been associated with
decreased levels of arousal (Volkow et al. 1995; Fiset et al. 1999).
We found that MD was bilaterally increased in the connectivity-
defined subregion projecting from thalamus to frontal cortex in
DLB as compared with controls. The thalamic nuclei serving pre-
frontal cortex play a relevant role in consciousness (Foucher et al.
2004; Ward 2011) and alertness (Tomasi et al. 2009). In particular,
deficits in concentration can be observed when thalamic region
projecting to prefrontal cortical network is damaged (Van Der
Werf et al. 1999). Moreover, in agreement with our findings, a
recent study showed that functional connectivity within thalamic
region projecting to frontal lobe was altered in DLB patients with
respect to controls (Kenny et al. 2013). However, we did not
observe a significant relationship between MD and CAF or FAB
scores. However, in some respects this is not unexpected as across
different neuroimaging modalities there has been an emphasis on
symptom in DLB being more reliant upon posterior cortical func-
tion (Imamura et al. 1999; Lobotesis et al. 2001; Pasquier et al.
2002; Kemp et al. 2007; Taylor et al. 2012; Delli Pizzi et al. 2014).
Indeed, in support of this we found that MD was bilaterally in-
creased in the connectivity-defined subregion projecting from thal-
amus to parieto-occipital cortex in DLB as compared with controls
although again there was no relationship between MD and CAF
for these projections. Therefore, while the integrity of thalamocor-
tical projections may be disrupted in DLB, this may be less rele-
vant to the pathophysiology of flCog; the 1H-MRS findings noted
above support an argument that intrinsic neurochemical changes
in the thalamus are more important, at least for flCog.
The ventrolateral region of thalamus and anterior portion of
pulvinar synchronize the activity across posterior cortical
regions, filtering distracters (Fischer and Whitney 2012) and
regulating visuospatial attention (Saalmann et al. 2012). Par-
ticularly, pulvinar is ideally situated to integrate bottom-up or-
ienting, driven either by sensory and subcortical inputs, with
top-down orienting, driven by goals and context (Ward 2011).
Notably, it was observed close relationship between pulvinar
lesion and visuo-attentional deficits (Arend et al. 2008). On
these bases, we propose that the deregulation of parieto-
occipito-thalamic connectivity could be related to alteration in
visual attention and visual dysfunction characterizing DLB
patients.
Furthermore, we observed that AD patients were affected by
bilateral microstructural damage in the connectivity-defined
subregion projecting from thalamus to temporal cortex. As as-
sessed by structural connectivity analysis, this connectivity-
defined subregion included the antero-ventral nuclei of
thalamus and the posterior pulvinar nuclei, which are directly
connected to hippocampus via the fornix and via the temporo-
pulvinar tract. The integrity of these connections is essential for
episodic memory (Aggleton and Brown 1999), which is specific-
ally affected in AD (Di Paola et al. 2007). In this context, Zarei
et al. (2010) reported that AD patients were affected by struc-
tural alteration of the antero-dorsal thalamic nuclei. Therefore,
we suggest that the microstructural alteration of connectivity-
defined subregion projecting from thalamus to temporal cortex
could be linked to great memory impairment affecting AD
patients.
In conclusion, our findings highlight the critical role of thal-
amus in DLB pathology. By multimodal techniques including
structural MRI, DTI, and 1H-MRS, we have shown, firstly, micro-
structural damage in thalamic regions related to alertness
and attention and, secondly, metabolic alterations related to
neuronal damage and cholinergic dysfunction in the thalami.
Furthermore, our results suggest that cholinergic imbalance
within thalami is closely linked to frequency and duration of
flCog occurring in DLB.
A possible limitation of our study is that we focused our ana-
lyses on DLB patients with flCog. Therefore our conclusions
may be less applicable to DLB without flCog. However, we
underline that in the present study a CAF score ≥2 was consid-
ered sufficient to define a patient as affected by flCog (Bonanni
et al. 2008), at difference with the study in which this scale was
originally proposed, where a higher cut-off of 5 at the CAF
questionnaire was shown to have high sensitivity and specifi-
city to DLB.
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